The US Food and Drug Administration's Circulatory System Devices advisory panel will meet on 27 October to review the premarket approval (PMA) application for Neovasc Inc.’s Reducer device, the company announced on 9 July.
Reducer is intended to treat angina, chest pain caused by poor blood flow to the heart’s muscle. It is a balloon-expandable, stainless steel frame with an hourglass shape, designed to be placed into the coronary sinus with a catheter intervention
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?